Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

400 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and immunogenicity of mRNA-based seasonal influenza vaccines formulated to include multiple A/H3N2 strains with or without the B/Yamagata strain in US adults aged 50-75 years: a phase 1/2, open-label, randomised trial.
Hsu D, Jayaraman A, Pucci A, Joshi R, Mancini K, Chen HL, Koslovsky K, Mao X, Choi A, Henry C, Vakil J, Stadlbauer D, Jorquera P, Arunkumar GA, Sanchez-Crespo NE, Wadsworth LT, Bhupathy V, Du E, Avanesov A, Ananworanich J, Nachbagauer R. Hsu D, et al. Among authors: ananworanich j. Lancet Infect Dis. 2024 Sep 5:S1473-3099(24)00493-6. doi: 10.1016/S1473-3099(24)00493-6. Online ahead of print. Lancet Infect Dis. 2024. PMID: 39245055
Safety and Immunogenicity of mRNA-1010, an Investigational Seasonal Influenza Vaccine, in Healthy Adults: Final Results From a Phase 1/2 Randomized Trial.
Ananworanich J, Lee IT, Ensz D, Carmona L, Schaefers K, Avanesov A, Stadlbauer D, Choi A, Pucci A, McGrath S, Kuo HH, Henry C, Chen R, Huang W, Nachbagauer R, Paris R. Ananworanich J, et al. J Infect Dis. 2024 Jun 27:jiae329. doi: 10.1093/infdis/jiae329. Online ahead of print. J Infect Dis. 2024. PMID: 38934845
Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis.
Lee IT, Nachbagauer R, Ensz D, Schwartz H, Carmona L, Schaefers K, Avanesov A, Stadlbauer D, Henry C, Chen R, Huang W, Schrempp DR, Ananworanich J, Paris R. Lee IT, et al. Among authors: ananworanich j. Nat Commun. 2023 Jun 19;14(1):3631. doi: 10.1038/s41467-023-39376-7. Nat Commun. 2023. PMID: 37336877 Free PMC article. Clinical Trial.
Seasonal influenza vaccine performance and the potential benefits of mRNA vaccines.
Russell CA, Fouchier RAM, Ghaswalla P, Park Y, Vicic N, Ananworanich J, Nachbagauer R, Rudin D. Russell CA, et al. Among authors: ananworanich j. Hum Vaccin Immunother. 2024 Dec 31;20(1):2336357. doi: 10.1080/21645515.2024.2336357. Epub 2024 Apr 15. Hum Vaccin Immunother. 2024. PMID: 38619079 Free PMC article. Review.
Mosaic vaccine-induced antibody-dependent cellular phagocytosis associated with delayed HIV-1 viral load rebound post treatment interruption.
Mdluli T, Slike BM, Curtis DJ, Shubin Z, Tran U, Li Y, Dussupt V, Mendez-Rivera L, Pinyakorn S, Stieh DJ, Tomaka FL, Schuitemaker H, Pau MG, Colby DJ, Kroon E, Sacdalan C, de Souza M, Phanupak N, Hsu DC, Ananworanich J, Ake JA, Trautmann L, Vasan S, Robb ML, Krebs SJ, Paquin-Proulx D, Rolland M. Mdluli T, et al. Among authors: ananworanich j. Cell Rep. 2024 Jun 25;43(6):114344. doi: 10.1016/j.celrep.2024.114344. Epub 2024 Jun 8. Cell Rep. 2024. PMID: 38850529 Free PMC article.
Adaptive NK Cells Rapidly Expand during Acute HIV Infection and Persist Despite Early Initiation of Antiretroviral Therapy.
Hearps AC, Zhou J, Agius PA, Ha P, Lee S, Price P, Kek H, Kroon E, Akapirat S, Pinyakorn S, Phanuphak N, Sacdalan C, Hsu D, Ananworanich J, Vasan S, Schuetz A, Jaworowski A; SEARCH010/RV254 and SEARCH013/RV304 Study Teams. Hearps AC, et al. Among authors: ananworanich j. J Immunol. 2024 May 15;212(10):1553-1563. doi: 10.4049/jimmunol.2300523. J Immunol. 2024. PMID: 38558245
Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials.
Happe M, Hofstetter AR, Wang J, Yamshchikov GV, Holman LA, Novik L, Strom L, Kiweewa F, Wakabi S, Millard M, Kelley CF, Kabbani S, Edupuganti S, Beck A, Kaltovich F, Murray T, Tsukerman S, Carr D, Ashman C, Stanley DA, Ploquin A, Bailer RT, Schwartz R, Cham F, Tindikahwa A, Hu Z, Gordon IJ, Rouphael N, Houser KV, Coates EE, Graham BS, Koup RA, Mascola JR, Sullivan NJ, Robb ML, Ake JA, Lyke KE, Mulligan MJ, Ledgerwood JE, Kibuuka H; VRC 208 and RV 422 study team. Happe M, et al. NPJ Vaccines. 2024 Mar 29;9(1):67. doi: 10.1038/s41541-024-00833-z. NPJ Vaccines. 2024. PMID: 38553525 Free PMC article.
Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: results from a multinational clinical trial.
Crowell TA, Ritz J, Zheng L, Naqvi A, Cyktor JC, Puleo J, Clagett B, Lama JR, Kanyama C, Little SJ, Cohn SE, Riddler SA, Collier AC, Heath SL, Tantivitayakul P, Grinsztejn B, Arduino RC, Rooney JF, van Zyl GU, Coombs RW, Fox L, Ananworanich J, Eron JJ, Sieg SF, Mellors JW, Daar ES; AIDS Clinical Trials Group (ACTG) A5354/EARLIER Study Team. Crowell TA, et al. Among authors: ananworanich j. AIDS. 2024 Jul 1;38(8):1141-1152. doi: 10.1097/QAD.0000000000003881. Epub 2024 Mar 13. AIDS. 2024. PMID: 38489580 Clinical Trial.
HIV-1 envelope diversity and sensitivity to broadly neutralizing antibodies across stages of acute HIV-1 infection.
VanderVeen LA, Selzer L, Moldt B, Parvangada A, Li J, Ananworanich J, Crowell TA, Eron JJ, Daar ES, Haubrich R, Geleziunas R, Cyktor J, Mellors JW, Callebaut C. VanderVeen LA, et al. Among authors: ananworanich j. AIDS. 2024 Mar 15;38(4):607-610. doi: 10.1097/QAD.0000000000003792. Epub 2023 Nov 16. AIDS. 2024. PMID: 38416554 Free PMC article.
Predictors of HIV rebound differ by timing of antiretroviral therapy initiation.
Li JZ, Melberg M, Kittilson A, Abdel-Mohsen M, Li Y, Aga E, Bosch RJ, Wonderlich ER, Kinslow J, Giron LB, Di Germanio C, Pilkinton M, MacLaren L, Keefer M, Fox L, Barr L, Acosta E, Ananworanich J, Coombs R, Mellors J, Deeks S, Gandhi RT, Busch M, Landay A, Macatangay B, Smith DM; AIDS Clinical Trials Group A5345 Study Team. Li JZ, et al. Among authors: ananworanich j. JCI Insight. 2024 Feb 8;9(3):e173864. doi: 10.1172/jci.insight.173864. JCI Insight. 2024. PMID: 38329130 Free PMC article.
400 results